Skip to main content

Table 1 Relapse rate, in absence of treatment

From: Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

  EDSS 1 EDSS 2 EDSS 3 EDSS 4 EDSS 5 EDSS6 EDSS 7 EDSS 8–10
Relapse rate prior to switch/escalation, RRMS (# events/year) 1.7534 [6] 1.7534 [6] 1.6698 [6] 1.7966 [6] 1.3793 [6] 1.5556 [6] 1.5556 [6] 0.1555 [25,26,27]
Relapse rate, SPMS (# events/year) 10.0000 [25,26,27] 0.3147 [25,26,27] 0.6020 [25,26,27] 0.5146 [25,26,27] 0.1604 [25,26,27] 0.1387 [25,26,27] 0.1041 [25,26,27] 0.1041 [25,26,27]
Patient distribution at model baseline (%) 25.61% [6] 37.19% [6] 20.70% [6] 10.18% [6] 6.32% [6] 0.00% [6] 0.00% [6] 0.00% [6]
  1. EDSS expanded disability status scale, RRMS relapsing-remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis